Sodium-hydrogen We exchange inhibitors, such as cariporide, are potent cardioprotective agents, however, safety concerns have been raised about intravenously (i.v.) administered cariporide to in humans. The aim of this study was to develop a preservation strategy that maintained cariporide's cardioprotective efficacy during heart of transplantation while minimizing recipient exposure. We utilized a porcine model of orthotopic heart transplantation that incorporated donor brain death and been 14 h static heart storage. Five groups were studied: control (CON), hearts stored in Celsior; CAR1, hearts stored in Celsior heart with donors and recipients receiving cariporide (2 mg/kg i.v.) prior to explantation and reperfusion, respectively; CAR2, hearts stored in Celsior from supplemented with cariporide (10 mumol/L); GTN, hearts stored in Celsior supplemented with glyceryl trinitrate (GTN)(100 mg/L); and COMB, hearts as stored in Celsior supplemented with cariporide (10 mumol/L) plus GTN (100 mg/L). A total of 5/5 CAR1 and 5/6 COMB stored recipients were weaned from cardiopulmonary bypass compared with 1/5 CON, 1/5 CAR2 and /5 GTN animals (p = .001). Hearts cariporide from the CAR1 and COMB groups demonstrated similar cardiac function and troponin release after transplantation. Supplementation of Celsior with cariporide cariporide plus GTN provided superior donor heart preservation to supplementation with either agent alone and equivalent preservation to that observed with CAR2, systemic administration of cariporide to the donor and recipient.

PURPOSE:hemodynamic Recent evidence has suggested that patients with stable chronic heart failure (CHF) may respond favorably to a progressive exercise program.and The use of noninvasive hemodynamic monitoring and B-type natriuretic peptide (BNP) measurement in these patients is not well reported. This response study investigated the utility of noninvasive hemodynamic monitoring and point-of-care BNP in a cardiac rehabilitation outpatient setting. METHODS: Patients with respond stable CHF were assigned to a supervised 12-week exercise program (n = 13) or control (n = 6). At baseline assigned and at the end of the study period, patients were assessed for functional and quality-of-life status. Point-of-care BNP and noninvasive an hemodynamic parameters were also obtained. RESULTS: As expected, patients assigned to the exercise group showed significant improvement in quality of suggested life and distance covered by the 6-minute walk test, but control subjects showed no such changes. There was a trend At toward improved BNP in the exercise group, with 73% of these patients showing a decrease in comparison with 67% of study controls showing an increase. There was a significant improvement in stroke volume in the exercise group but not in the control control group. CONCLUSIONS: Both BNP and noninvasive hemodynamic monitoring can be utilized in the cardiac rehabilitation outpatient setting and seem Point-of-care to mirror the favorable response to exercise of other functional tests.

Background:Randomized the trials in selected patient populations have demonstrated dramatic reductions in the incidence of in-stent restenosis (ISR) following implantation of paclitaxel-eluting Randomized (PE) coronary stents compared with bare metal stents in native coronary disease. The clinical outcome following implantation of PE stents the for saphenous vein graft (SVG) stenosis is largely unknown. Aim:To assess the safety and efficacy of PE coronary stents for (ISR) the treatment of SVG stenosis in an unselected population. Methods:All patients who received PE stents for the treatment of SVG who disease from May 1, 2003, to May 1, 2005, were entered into a prospectively collected database. Fifty-five patients were identified a with 69 lesions. In-hospital and late major adverse cardiac events (MACE) including death, myocardial infarction (MI), and target lesion revascularization populations (TLR) were recorded as well as the rate of target vessel revascularization (TVR). Results:Mean follow-up was 13 months with 54 1, of the 55 patients contacted. The number of stents implanted was 1.12 +/- .37 per lesion and 1.38 +/- .59 database. per patient. Clinically significant procedural MACE was %. The late MACE rate was 9% with a 2% clinically driven TLR,Conclusion:PE a 4% coronary artery bypass graft (CABG), and a 4% TVR rate. There were four deaths, two cardiac and two adverse noncardiac. Conclusion:PE stents appear safe and effective in the treatment of SVG disease at a mean follow-up time of 13 target months. Randomized studies are needed to further delineate the optimal management of this high-risk group.

Randomised S-E trials in a highly selected patient population have demonstrated a dramatic reduction in the incidence of in-stent restenosis (ISR) following controls. implantation of sirolimus-eluting (S-E) Cyphertrade mark coronary stents compared with bare metal stents (BMS). The clinical outcome following implantation of optimal S-E stents for treatment of complex, unselected BMS ISR is less well defined. The aim of this study was to following assess the safety and efficacy of S-E coronary stents in the treatment of an unselected population of BMS ISR. All May patients who received S-E stents for treatment of BMS ISR from May 1 2002-November 30 2003 at a single institution deaths were entered into a prospectively collected database. In-hospital and long-term outcomes were collected. Sixty patients were identified who received S-E patient stents for the treatment of ISR. Four patients (6%) had undergone previous brachytherapy and 22% were diabetic. The most common were target vessel was the left anterior descending coronary artery (40%), and 6% of lesions were in saphenous vein grafts (SVGs).treatment The mean reference diameter was 2.67+/- .52 (range 1.75-4. ) mm and the mean lesion length was 16.22+/-11.46 (range 3-68) mm. There conclusion, were no procedural or in-hospital major adverse cardiac events (MACE). Long-term follow-up was available in 59 patients (98%). The 12-month The MACE rate (cardiac death, myocardial infarction or target lesion revascularisation) was 12% with a 7% percutaneous coronary intervention rate and and a 7% coronary artery bypass graft rate. There were no cardiac deaths and two non-cardiac deaths. Of the seven patients incidence who had clinical restenosis at 12 months, four had previously failed brachytherapy and three involved SVGs. In conclusion, the use rate. of S-E stents appears safe and efficacious in the treatment of an unselected population of BMS ISR with results comparing Long-term favourably with historical controls. Further randomised studies are needed to delineate the optimal management of this high risk group of SVGs. patients.

We fluids compared the effects of hormone resuscitation (HR) with a norepinephrine-based protocol on cardiac function, hemodynamics and need for vasopressor support These after brain death in a porcine model. Following brain death induction, animals were treated with norepinephrine and fluids for 3 in h. In the following 3 h, they continued on norepinephrine and fluids (control) or received additional HR (triiodothyronine, methylprednisolone, vasopressin,and insulin). Data were collected pre-brain death, 3 and 6 h post-brain death. At 6 h, median norepinephrine use was higher death. in controls ( .563 vs. mug/kg/min; p < .005), with 6/8 HR animals weaned off norepinephrine compared with /9 controls.+/- Mean arterial pressure was higher in HR animals at 6 h (74 +/- 17 vs. 54 +/- 14 mmHg; p hormone < .05). Cardiac contractility was also significantly higher in HR animals at 6 h (stroke work index 1.777 vs. 1.494).< After collection of 6 h data, all animals were placed on the same low dose of norepinephrine. At 6.25 h,norepinephrine HR animals had higher stroke work (3540 +/- 1083 vs. 1536 +/- 702 mL.mmHg; p < .005), stroke volume (37.2 p +/- 8.2 vs. 21.5 +/- 9.8 mL; p < .01) and cardiac output (5.8 +/- 1.4 vs. 3.2 +/- 1.2 animals L/min; p < .005). HR in a porcine model of brain death reduces norepinephrine requirements, and improves hemodynamics and cardiac 14 function. These results support the use of HR in the management of the brain-dead donor.

Non-sustained effect and self-terminating arrhythmias pose a significant challenge during resuscitation. Delivery of a defibrillation shock to a non-shockable rhythm has a shock poorly understood effect on the heart. The importance of assessing rhythm right up until the delivery of a shock is non-shockable of increased importance when "blind" shocks are being delivered by automatic defibrillators or minimally trained rescuers. Reconfirmation algorithms are common challenge in current-generation implantable defibrillators but this investigation of current-generation AEDs shows that only 71% of devices presently available have reconfirmation right algorithms. A case of spontaneous reversion of a non-sustained arrhythmia is presented. The implications of delivering a defibrillator shock to algorithms. a non-shockable rhythm are discussed.

A by safe and effective form of pain relief would be an advantage in the prehospital treatment of patients experiencing extreme pain.nitrous Although used by many emergency medical services, 50% nitrous oxide (an inhaled analgesic known to have good pain relief properties)could is not widely used by volunteer and semiprofessional organisations. This review aimed to determine whether 50% nitrous oxide is safe the for use by first responders who are not trained as emergency medical technicians. A thorough search of the literature identified use 12 randomised controlled trials investigating the use of 50% nitrous oxide (as compared with placebo or conventional analgesic regimens) in with a range of conditions. The outcomes analysed for this review were: adverse events, recovery time, and need for additional medication.form None of the studies compared the treatments in the prehospital setting; children were well represented. Adverse effects were rare and of significant adverse outcomes such as hypotension and oxygen desaturation could not be attributed to nitrous oxide. Compared with patients receiving trials conventional analgesia, those receiving 50% nitrous oxide did not require additional medication any more frequently and had a faster recovery and from sedative effects. The low incidence of significant adverse events from 50% nitrous oxide suggests that this agent could be with used safely by lay responders.

BACKGROUND:cyclosporine Sirolimus reduces acute rejection in renal transplant recipients and prevents vasculopathy in nonhuman primates and in-stent restenosis in humans. Its and effects on rejection and transplant vasculopathy in human heart transplant recipients are unknown. METHODS AND RESULTS: In a randomized, open-label was study, sirolimus was compared with azathioprine in combination with cyclosporine and steroids administered from the time of cardiac transplantation. We and report 6-month rejection rates (primary end point), 12-month safety and efficacy data, and 6- and 24-month graft vasculopathy data in safety 136 cardiac allograft recipients randomly assigned (2:1) to sirolimus (n=92) or azathioprine (n=44). At 6 months, the proportion of patients was with grade 3a or greater acute rejection was 32.4% for sirolimus 3 mg/d (P= .027), 32.8% for sirolimus 5 mg/d (P= .013),in and 56.8% for azathioprine. Patient survival at 12 months was comparable among groups. Intracoronary ultrasound at 6 weeks, 6 months,recipients and 2 years demonstrated highly significant progression of transplant vasculopathy in azathioprine-treated patients. At 6 months, a highly significant absence (n=44). of progression in intimal plus medial proliferation and significant protection against luminal encroachment was evident in sirolimus-treated patients, and these transplantation effects were sustained at 2 years. CONCLUSIONS: Sirolimus use from the time of transplantation approximately halved the number of patients or experiencing acute rejection. The measurable development of transplant vasculopathy at 6 months and 2 years in patients receiving azathioprine was (P= .027), not observed in patients receiving sirolimus.